Jaejin An to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Jaejin An has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
1.315
-
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System. J Am Heart Assoc. 2021 02 02; 10(3):e019669.
Score: 0.701
-
Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023; 54(7-8):258-267.
Score: 0.207
-
Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease. Pharmacotherapy. 2021 12; 41(12):998-1008.
Score: 0.186
-
Treatment Patterns and Blood Pressure Control With Initiation of Combination Versus Monotherapy Antihypertensive Regimens. Hypertension. 2021 01; 77(1):103-113.
Score: 0.174
-
Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy. Pharmacoepidemiol Drug Saf. 2021 12; 30(12):1630-1634.
Score: 0.046